Watchlist Manager

Watchlist

Price: 9 460 KRW 2.83% Market Closed

Market Cap: ₩247.2B

	Hyundai Pharmaceutical Co Ltd KRX:004310	KR
	Zhejiang Lante Optics Co Ltd SSE:688127	CN
R	Resintech Bhd KLSE:RESINTC	MY

Balance Sheet

Currency: KRW

	Nov-2001	Nov-2002	Nov-2003	Nov-2004	Nov-2005	Nov-2006	Nov-2007	Nov-2008	Nov-2009	Nov-2010	Nov-2011	Nov-2012	Nov-2013	Nov-2014	Nov-2015	Nov-2016	Nov-2017	Nov-2018	Nov-2019	Nov-2020	Nov-2021	Nov-2022	Nov-2023	Nov-2024
Assets
Cash & Cash Equivalents	14 943	6 560	18 499	18 693	17 346	18 112	15 853	12 875	7 531	11 320	13 629	16 267	14 087	13 790	10 409	8 622	8 234	7 362	7 405	13 272	21 628	30 266	16 203	10 277
Cash Equivalents	14 943	6 560	18 499	18 693	17 346	18 112	15 853	12 875	7 531	11 320	13 629	16 267	14 087	13 790	10 409	8 622	8 234	7 362	7 405	13 272	21 628	30 266	16 203	10 277
Short-Term Investments	2 741	9 314	523	1 118	3 437	4 637	10 189	310	120	0	343	343	543	0	0	0	0	0	93	6 612	288	3 513	2 088	0
Total Receivables	27 476	32 779	32 378	33 709	36 185	37 630	38 481	46 396	55 078	52 405	55 969	45 322	44 763	46 003	47 280	54 267	59 598	43 829	45 100	42 358	40 336	42 461	38 973	38 652
Accounts Receivables	27 451	32 750	32 306	33 641	35 694	36 954	37 642	44 781	53 203	50 942	54 071	43 144	42 607	43 783	47 280	51 032	56 575	41 008	41 564	39 426	36 871	37 374	38 378	37 666
Other Receivables	25	29	72	68	491	676	839	1 615	1 875	1 463	1 898	2 178	2 156	2 220	0	3 235	3 023	2 821	3 536	2 932	3 465	5 087	595	986
Inventory	13 490	12 630	10 938	12 084	13 623	17 099	17 088	14 128	16 015	14 026	17 058	24 100	20 971	19 359	18 556	17 118	17 206	17 453	17 925	17 338	22 022	24 076	26 998	29 085
Other Current Assets	438	477	360	81	96	582	333	2 582	339	564	510	142	113	118	124	96	1 892	748	1 122	922	622	1 327	1 211	1 548
Total Current Assets	59 089	61 759	62 698	65 685	70 686	78 059	81 945	76 291	79 082	78 314	87 510	86 174	80 477	79 269	76 369	80 103	86 930	69 392	71 644	80 503	84 896	101 643	85 473	79 562
PP&E Net	26 569	27 879	27 568	26 772	26 479	28 380	35 429	47 737	46 320	43 167	40 726	33 097	33 346	32 705	32 454	32 655	33 000	32 015	30 592	29 567	29 261	28 601	29 436	37 446
PP&E Gross	26 569	27 879	27 568	26 772	26 479	28 380	35 429	47 737	46 320	43 167	40 726	0	0	32 705	32 454	32 655	33 000	32 015	0	29 567	29 261	28 601	29 436	37 446
Accumulated Depreciation	6 786	8 236	10 098	11 879	13 622	15 205	16 751	17 549	19 278	20 450	19 724	0	0	24 246	25 925	27 583	29 699	31 926	0	36 925	38 737	40 698	40 494	43 051
Intangible Assets	99	85	303	292	591	619	619	687	502	379	2 448	2 411	1 829	1 794	1 749	3 204	3 796	7 534	7 695	12 541	13 467	17 301	5 632	6 718
Note Receivable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	48	48	0	0	0
Long-Term Investments	5 143	5 190	4 580	4 710	4 370	6 174	5 126	4 936	7 010	7 375	24 325	25 832	26 020	31 978	34 421	30 574	29 474	30 743	30 457	28 814	29 312	29 793	30 555	27 721
Other Long-Term Assets	1 088	801	1 425	1 378	896	1 128	1 081	1 050	1 353	1 747	1 939	2 388	1 731	1 548	1 545	1 692	1 417	6 423	6 851	6 029	6 874	3 821	3 533	4 949
Total Assets	91 988 N/A	95 714 +4%	96 574 +1%	98 839 +2%	103 022 +4%	114 361 +11%	124 200 +9%	130 702 +5%	134 268 +3%	130 982 -2%	156 948 +20%	149 903 -4%	143 403 -4%	147 294 +3%	146 538 -1%	148 228 +1%	154 617 +4%	146 106 -6%	147 240 +1%	157 502 +7%	163 857 +4%	181 159 +11%	154 629 -15%	156 396 +1%
Liabilities
Accounts Payable	5 782	4 965	4 944	4 669	3 603	2 908	3 215	4 164	5 133	3 162	5 077	5 561	6 855	8 488	7 274	9 907	11 021	12 952	11 536	12 693	16 553	18 072	11 833	10 112
Accrued Liabilities	2 746	1 855	1 312	1 601	1 016	1 248	1 411	1 558	1 709	1 247	562	554	402	496	563	877	941	1 374	0	1 854	2 626	3 110	2 679	2 739
Short-Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	26 936	29 453	21 000	21 000	24 000	14 000	29 000	38 000	32 950
Current Portion of Long-Term Debt	183	270	727	0	49	0	0	19 002	23 522	22 000	27 819	29 286	20 750	18 764	21 000	0	0	0	0	416	521	352	624	331
Other Current Liabilities	14 025	11 187	9 002	8 498	9 561	9 689	11 574	8 594	7 821	9 064	11 599	8 418	8 637	8 190	8 651	6 804	7 602	14 179	16 882	12 816	12 151	30 162	12 198	12 555
Total Current Liabilities	22 735	18 278	15 986	14 768	14 229	13 845	16 200	33 317	38 185	35 473	45 057	43 820	36 644	35 938	37 488	44 524	49 017	49 505	49 418	51 779	45 850	80 696	65 334	58 687
Long-Term Debt	729	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	206	15 324	10 090	581	14 798
Deferred Income Tax	0	0	0	0	82	1 343	1 843	1 063	588	883	3 597	2 126	1 932	2 533	1 490	295	452	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0	460	462	507	0	0	0	0	0	0	0	0	0	0	0
Other Liabilities	2 641	5 534	5 258	5 601	5 336	4 258	2 789	3 690	2 897	2 121	3 978	4 270	3 615	4 137	3 128	5 646	7 049	8 476	13 644	15 376	16 082	3 818	4 053	3 837
Total Liabilities	26 105 N/A	23 812 -9%	21 244 -11%	20 369 -4%	19 647 -4%	19 445 -1%	20 833 +7%	38 071 +83%	41 670 +9%	38 477 -8%	53 092 +38%	50 678 -5%	42 697 -16%	42 608 0%	42 105 -1%	50 465 +20%	56 518 +12%	57 980 +3%	63 062 +9%	67 361 +7%	77 257 +15%	94 604 +22%	69 968 -26%	77 322 +11%
Equity
Common Stock	14 000	14 000	14 000	14 000	14 000	14 000	14 000	14 000	14 000	14 000	14 000	14 000	14 000	14 000	14 000	14 000	14 000	16 000	16 000	16 000	16 000	16 000	16 000	16 000
Retained Earnings	34 433	40 668	44 367	48 097	52 661	57 546	65 215	66 591	66 662	68 406	80 230	74 419	75 362	74 795	75 637	72 404	72 470	52 833	51 966	52 292	48 355	49 602	52 949	50 104
Additional Paid In Capital	2 842	2 819	3 040	3 303	3 949	7 010	6 684	6 684	6 386	6 386	6 386	6 386	6 386	6 386	7 092	7 610	7 610	15 718	35 381	20 471	20 471	20 654	20 654	20 654
Unrealized Security Profit/Loss	17 452	17 208	16 668	16 749	17 141	17 472	17 467	17 237	17 024	17 245	16 773	17 066	18 490	23 038	18 772	16 545	19 170	17 768	852	16 447	16 844	16 895	15 457	14 773
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	13 532	13 532	11 068	12 796	15 152	16 606	0	15 070	15 070	16 596	0	22 457
Other Equity	2 843	2 792	2 746	3 679	4 376	1 112	0	11 880	11 474	13 532	13 532	12 646	0	0	0	0	0	2 413	18 317	0	0	0	20 400	22 457
Total Equity	65 883 N/A	71 902 +9%	75 330 +5%	78 470 +4%	83 375 +6%	94 916 +14%	103 367 +9%	92 631 -10%	92 598 0%	92 505 0%	103 857 +12%	99 225 -4%	100 705 +1%	104 687 +4%	104 432 0%	97 763 -6%	98 098 +0%	88 126 -10%	84 178 -4%	90 141 +7%	86 600 -4%	86 555 0%	84 661 -2%	79 074 -7%
Total Liabilities & Equity	91 988 N/A	95 714 +4%	96 574 +1%	98 839 +2%	103 022 +4%	114 361 +11%	124 200 +9%	130 702 +5%	134 268 +3%	130 982 -2%	156 948 +20%	149 903 -4%	143 403 -4%	147 294 +3%	146 538 -1%	148 228 +1%	154 617 +4%	146 106 -6%	147 240 +1%	157 502 +7%	163 857 +4%	181 159 +11%	154 629 -15%	156 396 +1%
Shares Outstanding
Common Shares Outstanding	27	27	27	25	25	28	29	25	25	24	24	24	24	24	25	25	24	27	27	28	28	28	27	26

Income Statement Balance Sheet Cash Flow Statement

Hyundai Pharmaceutical Co Ltd
KRX:004310

Balance Sheet

Balance Sheet Decomposition
Hyundai Pharmaceutical Co Ltd

Balance Sheet
Hyundai Pharmaceutical Co Ltd

See Also

Company

Help

Tools

Stocks

Hyundai Pharmaceutical Co Ltd KRX:004310

Balance Sheet

Balance Sheet Decomposition Hyundai Pharmaceutical Co Ltd

Balance Sheet Hyundai Pharmaceutical Co Ltd

See Also

Company

Help

Tools

Stocks

Hyundai Pharmaceutical Co Ltd
KRX:004310

Balance Sheet Decomposition
Hyundai Pharmaceutical Co Ltd

Balance Sheet
Hyundai Pharmaceutical Co Ltd